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A B S T R A C T
Nanocarrier-mediated transmucosal drug delivery based on conventional mucoadhesive, muco-inert or mucus-
penetrating nanoparticles (NPs) is a growing ﬁeld especially in challenging diseases like cystic ﬁbrosis (CF).
Eﬃcacy of such systems dictates profound investigation of particle-mucus interaction and factors governing the
whole process. Although variable techniques studying particle diﬀusion in mucus have been introduced, stan-
dardized procedures are lacking. The study comprised diﬀerent methods based on micro- and macro-displace-
ment as well as colloidal stability and turbidimetric experiments. Artiﬁcial sputum medium (ASM), CF sputum
and mucus-secreting cell line (Calu-3 air interface culture, AIC) were applied. Solid lipid nanoparticles (SLNs)
coated with variable hydrophilic sheath (poloxamer, Tween 80 or PVA) represented the nanocarriers under
investigation. Both micro-displacement studies based on single particle tracking and macro-displacement ex-
periments based on 3D-time laps confocal imaging revealed faster diﬀusion of poloxamer- > Tween- > PVA-
coated SLNs. Compared to ASM, CF sputum showed not only lower diﬀusion rates but also remarkable dis-
crepancies in particle-mucus diﬀusion rate due to sputum heterogenicity. Meanwhile, in case of Calu-3 AIC,
thickness of the mucosal layer as well as density of mucus network were key determinants in the diﬀusion
process. The points emphasized in this study highlight the road towards in vivo relevant particle-mucus inter-
action research.
1. Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive genetic condition
mainly manifested in the lungs. Owing to mutations in the gene coding
for the CF Transmembrane Conductance Regulator (CFTR) that nor-
mally regulates ion (chloride and sodium) ﬂux across the cell mem-
brane, dehydration of the airway surface liquid and impairment of
mucociliary clearance take place. This in turns alters the appearance
and composition of respiratory mucus and leads to serious complica-
tions like airway obstruction, chronic lung infection, and inﬂammatory
reactions [1]. The treatment goals for patients with CF lung disease
either to halt or slow disease progression are limited by several barriers.
As compared with normal airway secretions, CF mucus has a higher
consistency because of a high content of actin, serum proteins, DNA,
alginate, and rigidifying lipids [2]. These negatively charged biopoly-
mers (mucin, DNA, and alginate) are connected to each other through
physical entanglements of their chains and non-covalent interactions
such as electrostatic, hydrogen, and hydrophobic bonding resulting in a
viscoelastic network [3]. Such ﬁrm mucus blanket represents a chal-
lenging barrier in CF therapy [2].
Although the incorporation of drugs and genes in nanocarriers
proved potential for localized and sustained delivery to mucosal tissues,
their eﬃcacy is strongly limited under certain disease conditions [2].
Conventional transmucosal delivery was mainly based on mucoadhe-
sive systems, where particle association with mucus was maximized to
prolong the residence time [4,5]. Although many reports supported the
notion that mucoadhesive particles increased drug bioavailability, the
transit time and per se the eﬃcacy are determined by the physiological
turnover time of the mucus layer [6,7]. Many NPs get caught in the
superﬁcial mucus by steric hindrance or adhesion processes and do not
eﬃciently reach neither the deeper mucus layers nor the underlying
epithelium. The development of particulate carrier systems rapidly
penetrating the mucus gel layer, skipping mucin turnover and reaching
the absorption membrane is therefore of ultimate interest and
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represents an attractive trend in transmucosal drug delivery [6].
Literature surveys classiﬁed mucus-penetrating nanoparticles
(MPNs) into active and passive systems. Passive systems try to avoid
interactions of particles with mucus based on surface hydrophilicity,
while active systems interact with mucus making it leakier for particles
[8,9]. The latter are mainly based on disulphide bridge breaking agents
and on proteolytic enzymes [10–13]. Referring to the passive strategy,
we previously developed mucus-penetrating solid lipid nanoparticles
(SLNs) and lipid nanocapsules in presence of diﬀerent emulsiﬁers with
variable hydrophilicity for the management of CF [14,15]. Earlier re-
ports investigated the impact of particle size, charge and surface hy-
drophilicity on particle-mucus penetration [2]. A diversity of additives
were also studied to overcome the barrier properties of mucus including
recombinant human deoxyribonuclease (DNAse) and N-acetyl cysteine
[2]. In such cases, latex beads, polystyrene and PLGA nanoparticles
were used [8,16–19]. Mucus from variable sources was applied (e.g.,
pig intestinal mucus, human cervicovaginal mucus, CF sputum)
[2,18,20]. To our knowledge, that would be the ﬁrst approach in-
vestigating the penetration of lipid-based nanocarriers (SLNs) in CF
sputum from human origin.
As every hypothesis necessitates a proof, settlement of standardized
methods and techniques allowing precise and accurate evaluation of
mucus-particle interactions is hence substantial for the proper design
and development of more eﬃcient MPNs.
Diﬀerent methods to determine particle diﬀusion in mucus have
been introduced including the Transwell diﬀusion system and rotating
silicone tube technique both assessing the macro-displacement of na-
noparticles in mucus, as well as single particle tracking (SPT) and dif-
fusion NMR dealing with the micro-displacement of nanoparticles
(details were reviewed by Grießinger et al. [21]). Meanwhile, small-
angle neutron scattering (SANS) can be considered as an appropriate
analysis technique for studying the molecular interactions between
drug carrier and mucus. Our group also introduced optical tweezers and
atomic force microscopy for studying the interaction of various parti-
cles with native respiratory mucus from horses [22]. For all particle-
mucus interaction studies, the type of mucus and its preparation is
crucial. Indeed, harmonization/standardization of these diﬀerent
techniques is still lacking.
As overcoming the mucus barrier remains one of our scopes, a new
approach based on 3D-time laps imaging was used to investigate the
mucus penetrating potential of SLNs [14,23]. However, only artiﬁcial
sputum medium (ASM) was applied during the study, which might not
serve as a proper substitute for CF sputum. At the current stage, several
crucial points are to be addressed: (i) estimating the rate and extent by
which SLNs go deeply in the mucus layer to act as depot for the payload
in relation to their surface properties; (ii) correlation between micro-
displacement studies of particle-mucus penetration data by SPT and
macro-displacement experiments in ASM, CF sputum and Calu-3 cells;
(iii) discrepancies between mucus penetration studies carried out using
ASM, native CF sputum and mucus-secreting cell lines.
2. Materials and methods
2.1. Materials
Glyceryl behenate (Compritol 888 ATO, C) was kindly donated by
Gattefossé, Saint-Priest, France. Nile Red (NR), mucin from porcine
stomach-Type II, DNA (low molecular weight from salmon sperm),
diethylenetriaminepentaacetic acid (DTPA), Trizma base, sodium
chloride, potassium chloride, Poloxamer 407 (Pluronic® F-127, P) and
Polysorbate 80 (Tween 80, Tw) were purchased from Sigma-Aldrich,
Steinheim, Germany. Polyvinyl alcohol (Mowiol 4-88, PVA) was ob-
tained from Kuraray Europe GmbH, Hattersheim am Main, Germany.
Alexa Fluor-labelled wheat germ agglutinin (WGA) was received from
Invitrogen, Oregon, USA. Egg yolk emulsion was obtained from Oxoid
Ltd, Kampshire, UK. BactoTM Casamino acid was purchased from Difco
Laboratories, Becton, Dickinson and Company, MD, USA. Hydroxyethyl
cellulose 250M (HEC) was received from SE Tylose GmbH & Co. KG,
Wiesbaden, Germany.
2.2. Methods
2.2.1. Preparation & characterization of plain and labelled SLNs
Plain SLNs (denoted by C-PVA-SLNs, C-P-SLNs, and C-Tw-SLNs)
were prepared using compritol as the lipid core with one of the fol-
lowing emulsiﬁers (PVA, Poloxamer 407 and Tween 80) to provide
variable surface properties as previously described [14]. Compritol
(0.2% w/v) was melted at 80 °C. Aqueous solution of the emulsiﬁer
(kept at the same temperature) was added to the molten lipid during
sonication (30–32 W for 3min, intermittent). The mixture was further
homogenized at 8000 rpm for 15min. Particles were allowed to solidify
by gentle stirring at room temperature.
SLNs labelled with Nile Red were prepared using the same protocol
after adding a solution of Nile Red in DMSO (5 µg/ml) to the molten
lipid.
The colloidal properties (average particle size, polydispersity (PdI)
and ƺ-potential) of SLNs were measured using Malvern Zetasizer Nano
ZS (Malvern, UK). Particle morphology was examined by scanning
electron microscopy (SEM) (Zeiss EVO HD, Zeiss, Oberkochen,
Germany).
2.2.2. Preparation of mucin solution, hydroxyethyl cellulose (HEC)
solution, artiﬁcial sputum medium (ASM) and collection of CF sputum
Mucin solution was prepared by dissolving mucin (0.8% w/v) in
deionized water while stirring (magnetic stirrer, 900 rpm). Solution was
ﬁltered prior to use in further experiments and stored at 4 °C.
HEC aqueous solution (1% w/v) was prepared by overnight stirring
in water.
ASM was prepared as previously described [24]. Brieﬂy, to prepare
1 L ASM, DNA and mucin were separately dissolved in sterile water
(250ml) for several hours. DTPA, sodium chloride and potassium
chloride were dissolved in 100ml water, while casamino acid was se-
parately dissolved in a similar volume of water. Finally, egg yolk was
added and pH was adjusted to 6.9 using Tris Buﬀer (1 M, pH 8.5).
CF-sputum: After approval by the Ethics Committee of the
University Hospital of Ghent, sputum was obtained from CF patients
who attended the hospital. The sputum was produced spontaneously
during respiratory therapy. After collection, sputum samples were im-
mediately frozen at −20 °C until use.
2.2.3. Rheological measurements of artiﬁcial- and CF-sputum samples
To determine the macroscopic viscoelastic properties of artiﬁcial-
and CF-sputum samples, a cone/plate rheometer (Haake™ MARS™
Modular Advanced Rheometer System, Thermo Fischer Scientiﬁc,
Waltham, MA, USA) was used. Cones with 1° and 0.5° angle (C60/1,
C60/0.5) were applied for ASM and CF-sputum, respectively.
Rheological investigations were performed at a frequency of 0.5 Hz and
a sheer stress range of 0.02–2 Pa using CR (Controlled Rate) and CD
(Controlled Deformation) modes for ASM and CF-sputum samples, re-
spectively. Measurements were carried out at room temperature and
37 °C in triplicates. The eﬀect of HEC on the viscosity of ASM was in-
vestigated. In case of CF sputum, frequency sweep was used to de-
termine the elastic and viscous moduli (G′ and G″). Data were analysed
using HAAKE RHEOWIN JobManager software.
2.2.4. Studying SLN-mucus interaction
2.2.4.1. Monitoring colloidal stability of SLNs. SLNs were incubated with
mucin solution (0.8 %w/v) up to 4 h at 37 °C. At predetermined time
intervals, the size, PdI and ƺ-potential were monitored.
2.2.4.2. Turbidimetric measurements. In addition, the absorbance of
SLNs, mucin as well as SLN-mucin mixtures was measured at 650 nm
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to record any signs of turbidity/agglomeration (Lambda 35,
PerkinElmer LAS, Rodgau, Germany) [25].
2.2.4.3. Single particle tracking (SPT) measurements. Single particle
tracking microscopy was performed as described before [26]. In brief,
ﬂuorophore excitation was done with two solid state lasers (100 mW
Calypso 491 nm, Cobolt, Solna, Sweden; 100 mW Spectra Physics
Excelsior 642 nm, Newport, Irvine CA, USA) that were coupled into a
TE2000-E inverted microscope (Nikon BeLux, Brussels, Belgium). Time-
lapse images were recorded with a Plan Apo VC 100x 1.4NA oil
immersion objective lens (Nikon) and an EMCCD camera (Cascade
II:512; Roper Scientiﬁc, Tucson, AZ, USA). Following particle
identiﬁcation in the SPT movies by an in-house developed software,
trajectories were calculated according to the nearest neighbour
principle. For each trajectory, the mean squared displacement (MSD)
was calculated for the available time lags (i.e. multiples n of the time Δt
between the images). These data were ﬁtted with
= − +MSD t n t σ tΓ 1/3Γ Δ 4 (Γ/4, Δ )α 2
,where Γ is the transport coeﬃcient, Δt the image acquisition time, and
σ the localization precision that depends on both Γ and Δt. The
anomalous exponent α is a measure for the mode of diﬀusion,
allowing interpretation of the trajectories according to free diﬀusion
(α=1), anomalous subdiﬀusion (α < 1) and superdiﬀusion (α > 1).
Additionally, the apparent diﬀusion coeﬃcient Da corresponding to the
ﬁrst time-lag Δt was calculated using the formula:
=D MSD t/4Δa
,resulting in a distribution of diﬀusion coeﬃcients which was further
reﬁned with a maximum entropy analysis. This improves the precision
of the distributions and removes features (noise) from the distributions
that are not statistically warranted by the data [27].
2.2.4.4. 3D-time laps confocal microscopy in ASM and CF sputum. The
diﬀusion of NR-labelled SLNs in both ASM and CF sputum stained with
Alexa Fluor-488-WGA was investigated by 3D-time laps imaging using
CLSM. Brieﬂy, constant volume of sputum was ﬁlled in multi-
compartment chamber slides and horizontally shaken to get equally
thick mucus layers.
At zero time, a predetermined volume of SLN dispersions was in-
stilled on the sputum surface. Z-stacks (images of 20 planes at various
depths) were immediately recorded along 20 µm distance in the sputum
sample. Confocal images (270×270 µm) were made at a ﬁxed plane
below the surface of the mucus layer. The same imaging procedure was
repeated for the same area with the same setting at diﬀerent time in-
tervals. Stained sputum samples were examined as control. AlexaFluor-
488-WGA and Nile Red were excited with the 488 nm argon laser line
and 561 nm helium-neon laser line, respectively.
All z-stacks obtained were analysed by Image J software for ﬂuor-
escence intensity. The eﬀect of emulsiﬁer type (Tween, PVA and po-
loxamer) on SLN surface on particle diﬀusion was studied. In addition,
the potential use of ASM to substitute CF sputum in these studies was
evaluated.
By imaging a volume with well-deﬁned thickness/height (z-value)
we can eliminate ill-deﬁned thickness of the mucus layer when evalu-
ating diﬀusion times of the particles in the respective gel matrix (ASM).
2.2.5. Studying penetration of SLNs on mucus-secreting cell lines
2.2.5.1. Calu-3 cells (air-interface culture, AIC). Calu-3 cells grown
using AIC were identiﬁed to generate more columnar epithelium with
apical cilia-like protrusions, more pronounced glycoprotein secretion as
well as higher level of ZO-1 protein compared to liquid-covered culture
(LCC). AIC model is thus more morphologically representative to the
airway epithelium. Cells (105 cell/ml) were seeded in 12-well Transwell
plate and grown in LCC using MEM supplemented with 10% foetal calf
serum, FCS, 1% sodium pyruvate, penicillin/streptomycin as culture
medium. After 48 h, the culture medium was withdrawn from cell
surface and the cells were allowed to grow for 14–16 days till a
conﬂuent monolayer was obtained. Trans-epithelial electrical
resistance (TEER) values were monitored after adding culture
medium to the apical compartment, which was then removed after
measurement. TEER values ≥300Ω·cm2 indicated tight monolayer.
2.2.5.2. Deposition of nebulized NR-SLNs on Calu-3 cells using
VITROCELL®. Transwell inserts containing AIC of Calu-3 cells were
transferred to VITROCELL® Cloud System 12 (VITROCELL Systems
GmbH, Waldkirch, Germany). The setup is speciﬁcally designed for
dose-controlled and spatially uniform deposition of liquid aerosols on
cells cultured at the air-liquid interface. Aeroneb® Lab nebulizer
allowed the generation of aerosol cloud of NR-SLNs (0.5 mg/ml) for
approx. 3–4min that uniformly deposit over the cell surface. The
apparatus was equipped with a quartz crystal microbalance for dose
monitoring.
2.2.5.3. Viability assay. Verifying the viability of Calu-3 cells AIC was
essential to prove maintenance of cell viability and integrity during
nebulization and incubation with the labelled particles (NR-C-P-SLNs,
NR-C-Tw-SLNs, and NR-C-PVA-SLNs). Following exposure and particle
deposition using VITROCELL®, Transwell inserts were transferred back
to the incubator enabling SLN-cell contact for 4 and 24 h. Samples were
then removed, cell surface washed twice with PBS and incubated for 3 h
with MTT solution (0.05 %w/v). Formazan crystals were dissolved
using isopropanol and absorbance was measured at 550 nm. Cell
viability was determined relative to positive and negative controls of
untreated cells and cells treated with Triton X, respectively. Experiment
was done in quadruplicate.
2.2.5.4. Mucus staining & penetration studies using CLSM. In this case,
cells with deposited labelled particles were further incubated for
diﬀerent time periods (0.5–24 h). Monolayers were then washed
twice with PBS. The mucus layer was stained with AlexaFluor-488-
WGA (10 µg/ml) for 10min at 37 °C. Following a washing step with
PBS, the membrane inserts holding the cell monolayer were separated
from the plastic support, mounted on a microscope slide and covered
with coverslips.
To investigate the extent of diﬀusion in mucus on the cell surface,
samples were directly visualized by 3D-time laps imaging using CLSM
with the same setup described in Section 2.2.4.4.
3. Results & discussion
3.1. Colloidal characteristics of SLNs
Plain and labelled compritol-based SLNs were prepared as pre-
viously described [14]. The colloidal properties seemed to be inﬂu-
enced by the emulsiﬁer used; a mean size of 81, 155 and 215 nm was
recorded for poloxamer-, Tween- and PVA-stabilized particles, respec-
tively, Table 1. The ƺ-potential ranged from high (−24.4mV), to
moderate (−14.7mV), to weakly negative (−3.73mV) for poloxamer-,
Tween- and PVA-coated SLNs, respectively. Pluronics are generally
triblock copolymers of polyethylene oxide-polypropylene oxide-poly-
ethylene oxide (PEO-PPO-PEO), the hydrophobic PPO tend to adsorb on
nanoparticle surface allowing the hydrophilic segments of PEO to
protrude. Pluronic F-127 is reported to have relatively longer hydro-
phobic PPO units (MW > 3KDa) that enable ﬁrm anchoring of copo-
lymer on NP surface with dense hydrophilic PEO brush. The latter plays
a great role in shielding the charge of the particle core if any and re-
ducing the overall ƺ-potential. According to Yang et al., this net charge
inﬂuences particle diﬀusivities in mucus; the nearly neutral particles’
surface tend to shield PLGA and latex particles from mucoadhesion
[17].
Labelling SLNs with Nile Red generally resulted in considerable, yet
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acceptable, increase in size and PdI, Table 1.
3.2. Macro-rheological data (viscosity, G′, G″)
The rheological characteristics of the mucus samples were thought
to deﬁne the rate and extent of particle penetration. In the current
study, diﬀerent types of mucus samples were investigated (ASM, ASM
+HEC and CF mucus).
As shown in Fig. 1A, the viscosity of ASM at room temperature was
not aﬀected by the shear stress indicating a Newtonian behaviour
(2.34 mPa). The addition of HEC signiﬁcantly raised the viscosity by 10-
fold (24.3 mPa) and changed the system to shear-thinning, Fig. 1A.
Increasing the temperature to 37 °C resulted in a relative reduction in
viscosity for both solutions tested, Fig. 1B.
For preparing ASM, mucin from porcine stomach type II (Sigma
Aldrich) was used; this has been exposed to proteolytic action during
isolation. Accordingly, the mucin structure has been irreversibly altered
and will not form a gel when concentrated 4x the level that is present in
the native mucus gel. HEC is reported to have micro-rheological
properties mimicking mucus [22]. Therefore, it was selected to impart
viscosity to ASM. Similar attempts have been made to generate a bio-
similar intestinal mucus using sigma pig mucin by adding lipid, bovine
serum albumin and polyacrylic acid. Although this resulted in similar
rheological moduli (e.g. G′ and G″) to porcine intestinal mucus, the
charge on the gel, its interactions and size ﬁltering properties were
reported to be diﬀerent [28].
The viscoelastic proﬁles of CF sputum at room temperature and
37 °C are presented in Fig. 1C–F. At low strain, a distinct linear vis-
coelastic region was observed, followed by certain increase in the vis-
cous modulus G″ upon increasing the strain, Fig. 1D. This is contra-
dicting the shear-thinning properties observed with pig intestinal
mucus, a classical feature of mucus secretions [18]. Higher values of G′
compared to G″ might also reveal the pronounced elastic gel properties
of CF sputum samples. At body temperature, lower elastic moduli G′
and G″ were recorded at lower frequency levels together with a stronger
frequency dependence of the moduli compared to those obtained at
room temperature. Mucus rheology is normally governed by both vis-
cous drag from interstitial ﬂuids within the mesh spacing and elastic
recoil from the mesh ﬁbres. According to shear stress, mucus might also
act as a viscous liquid or an elastic solid, which can be described by a
foam model [29]. The rheological properties of mucus diﬀer as a
function of shear stress, shear rate and length scale [30]. It is also to be
noted that sputum may undergo physical degradation after its collec-
tion, through the action of endogenous and bacterial proteases as well
as dehydration during the measurements [2].
Interactions between nanocarriers and mucus layer are usually ex-
pected to modify the viscoelasticity of mucus which can be detected via
rheological studies [2,21]. Rheological synergism has been proposed as
an in vitro parameter to determine the mucoadhesive properties of
polymers: the higher the rheological synergism, the stronger the par-
ticle interactions with mucin [31]. In the current study, studying mu-
coadhesion to improve transmucosal drug delivery was not our target.
Rheological measurements were restricted only to deﬁne discrepancies
between the artiﬁcial and native sputum used along the rest of the
studies to help correlating with the upcoming particle diﬀusion data.
Indeed, such classical bulk rheological techniques remain incapable of
probing viscous and elastic characteristics at the submicron length scale
[20]. Noteworthy, the microscale rheology of mucus may be altered,
without aﬀecting the macrorheological properties.
3.3. Colloidal stability of SLNs in mucus
The contact between negatively-charged mucus and nanoparticulate
drug delivery systems can inﬂuence the physico-chemical properties of
such nanoparticles. Surface properties of charged nanoparticles were
tested after incubation with mucus. Alterations in these propertiesTa
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should give information about a possible adsorption of mucus to the
particles indicated by a change in ƺ-potential and/or an increase in
particle size.
In most cases, size data are represented as Z-average, denoting a
mean hydrodynamic diameter based on intensity distribution data,
which in our opinion would not reﬂect the actual interaction possibly
taking place between the particles and mucus. Accordingly, size
measurements here were illustrated as number-based distribution
curves, Fig. S1 (supplementary materials), that allows the observation
of peak shift along the incubation period. The superimposed size dis-
tribution curves obtained during 3 h incubation of poloxamer-stabilized
SLNs with ASM reﬂect minor particle-mucus interaction, Fig. S1A. In
contrast, PVA-stabilized SLNs showed clear shift indicating signiﬁcant
interaction, Fig. S1C. Interestingly, Tween-stabilized SLNs exhibited a
Fig. 1. Rheological properties of (A) ASM, room temperature; (B) ASM, 37 °C; (C) G′, CF sputum, room temperature; (D) G″, CF sputum, room temperature; (E) G′, CF sputum, 37 °C; (F)
G″, CF sputum, 37 °C.
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notable size distribution shift directly after incubation with ASM, Fig.
S1B. This shift remained however stable during the whole incubation
period, which might deduce the formation of stagnant coat of ASM
around the particles. This rough ranking is to be taken into considera-
tion while discussing the diﬀusion experiment data.
Zeta potential measurements were in accordance with previous re-
ports [21]; negatively-charged nanoparticles apparently exhibited no
physico-chemical modiﬁcations after incubation with negatively-
charged mucus (refer to zeta potential values in the supplementary
material, Table S1). In contrast, mucus might coat positively-charged
particles such as chondroitin sulphate-chitosan nanoparticles with a
layer owing to electrostatic interactions resulting in alterations of these
particle physico-chemical properties [13]. Despite the insigniﬁcant
changes in zeta potential, the increase in size in case of PVA-stabilized
SLNs might be referred to physical binding forces other than charge
interaction presumably arising from entanglement of absorbed mucus
networks around particles causing particle bridging. This shielding was
interpreted as notable, yet constant enlargement in particle size.
3.4. Turbidimetric measurements
Possible aggregation due to particle-ASM interaction could be
manifested as increased turbidity with time. Samples from the afore-
mentioned experiments were assessed turbidimetrically. As shown in
Fig. 2. (A) Apparent diﬀusion coeﬃcient and (B) α-values of SLNs in ASM, (C) apparent diﬀusion coeﬃcient and (D) α-values of SLNs in CF sputum measured by MPT.
NR-C-Tw SLNs & ASM MSA&sNLSAVP-C-RNMSA&sNLSP-C-RN
Control ASM
t=0
t=2h
t=1h
t=0.5h
t=0.25h
20
 μ
m
Fig. 3. Z-stacks of particle diﬀusion (red) in ASM (green) as a function of time: (A) C-P
SLNs; (B) C-Tw SLNs; (C) C-PVA SLNs. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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ACF sputum t = 0 t = 30 min
t = 1 h t = 2 h
B
CF sputum t = 30 mint = 0
t = 1 h t = 2 h t = 3 h
t = 3 h
C
CF sputum t = 30 mint = 0
t = 1 h t = 2 h t = 3 h
Fig. 4. Z-stacks of particle diﬀusion (red) in CF
sputum (green) as a function of time: (A) C-P SLNs;
(B) C-Tw SLNs; (C) C-PVA SLNs. (For interpretation
of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Table 2a
Colloidal characteristics of compritol-based SLNs after nebulization.
Formula code After nebulization
Mean diameter ± SDa (nm) PdI ± SD ƺ-potential ± SD (mV)
C-P SLNs 199 ± 6.77 0.553 ± 0.006 −14.3 ± 0.06
C-Tw SLNs 137.8 ± 1.834 0.373 ± 0.007 −9.03 ± 0.661
C-PVA SLNs 304.1 ± 8.55 0.335 ± 0.055 −16.4 ± 1.1
a SD denotes standard deviation (n= 3).
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Fig. S2, no obvious changes in transmittance could be noted even with
PVA-stabilized SLNs that showed shift in size distribution curves de-
scribed in Section 3.3. This might postulate that the increase in size did
not interfere with the colloidal stability of the particles and did not
result in aggregate formation and turbidity. In other words, this tech-
nique was not precise enough to reveal the aforementioned interaction.
In contrast, similar studies using SLNs were simply based on turbidi-
metric measurements [32].
3.5. Micro-displacement studies of SLNs in ASM and CF sputum by SPT
SPT involves the tracking of the motion of individual particles
within a particular matrix followed by post-acquisition diﬀusion ana-
lysis [33,34]. The movement of particles is translated into individual
particle trajectories. For each trajectory, the mean square displacement
(MSD) is calculated as a function of time lag Δt (i.e. the time between
positions in the trajectory). A ﬁtting of the anomalous diﬀusion model
returns the anomalous diﬀusion exponent α, which can be used to
classify trajectories in terms of subdiﬀusion ( <α 1), free diﬀusion
( =α 1) and superdiﬀusion ( >α 1) [35]. In addition, one can calculate
an ‘apparent diﬀusion coeﬃcient’ for a given time-lag according to
=D MSD t/4Δa tΔ . In this work, we have calculated Da at the shortest
possible time lag tΔ (i.e. the time between two neighbouring points in
the trajectory), which represents the apparent instantaneous diﬀusion
coeﬃcient.
In the current study, SPT was used to investigate SLNs interaction
with ASM and CF sputum. In case of ASM, no appreciable diﬀerence
was found in the instantaneous diﬀusion coeﬃcient of SLNs regardless
of the type of emulsiﬁer used, Fig. 2A. While most particles exhibited
free diﬀusion, the distribution of α-values for all formulations was
slightly skewed to smaller values, indicative that a fraction of the
particles are experiencing hindered diﬀusion, Fig. 2A. Regardless of the
formulation, no physicochemical interaction with ASM components
could be recognized to perturb the movement of SLNs. Diﬀerences in D
in relation to emulsiﬁer type were minimal; a small shift in the curve
could be noticed in the order (Tween > poloxamer > PVA). In addi-
tion, α-values of most particles were around 1 revealing non-hindered
diﬀusional behavior, Fig. 2B. This is in accordance with the rheological,
size and turbidimetry data described above except for PVA-stabilized
SLNs.
In comparison, the D distribution curves reﬂect clear binding and
restricted diﬀusion between SLNs and components of the CF sputum,
Fig. 2C. Moreover, Tween- and PVA-coated SLNs show higher interac-
tion compared to poloxamer-coated ones; α-values were shifted to
lower values (less than 1), Fig. 2D, generally described as ‘sub-diﬀusive’
[36]. α values in case of C-Tw and C-PVA SLNs could be observed be-
tween 0.2 and 0.9 indicating varying degrees of hindrance to particle
movement [8]. A signiﬁcant percentage of the particles showed α va-
lues of less than 0.2, hence are considered to be completely im-
mobilized.
Unlike particle diﬀusion in ASM, which is relatively non-restrictive,
particles do undergo varying degrees of perturbation during their dif-
fusion through a viscous gel matrix such as CF sputum [37]. The
structure of the 3D sputum network is to be considered; CF sputum
contains a high concentration of biopolymers that form an increased
number of junctions between biopolymer chains per unit volume of
sputum leading to signiﬁcant viscoelasticity [2]. Even ﬂuids between
the CF sputum mesh have markedly higher concentrations of free bio-
polymers, including DNA and actin fragments, rendering the micro-
viscosity signiﬁcantly higher. The viscosity of ﬂuids within the pores of
CF sputum was previously estimated, based on the diﬀusion of dextran
in CF sputum, to be roughly 2.9-fold higher than water [16].
3.6. 3D-time laps confocal microscopy of SLN diﬀusion in ASM and CF
sputum
Along with SPT experiments monitoring SLN micro-displacement in
mucus, exploring particle macro-displacement behaviour is funda-
mental. The diﬀusion of SLNs in ASM was monitored using 3D-time laps
CLSM imaging. Fig. 3 represents the Z-stacks of control ASM as well as
NR-labelled SLNs samples in ASM at diﬀerent time intervals. Control
ASM stained in green appeared homogeneous. Poloxamer-stabilized
SLNs were the fastest to diﬀuse in ASM followed by Tween-, then PVA-
stabilized SLNs; the ﬁrst appearance of red-labelled SLNs was 0.25, 0.5
and 2 h post incubation for NR-C-P, NR-C-Tw and NR-C-PVA SLNs, re-
spectively, Fig. 3.
In a similar study by Ungaro et al. [19], the experiment was carried
out in 24-well plates containing a layer of solidiﬁed gelatine in the
bottom, followed by an ASM layer. Diﬀused particles were quantiﬁed in
the gelatine layer spectroﬂuorimetrically 24 h after incubation [19].
The study, however, did not investigate the particle diﬀusion rate
within the ASM layer. Besides, 24 h incubation could be considered
extensively long relative to the in vivo conditions.
Fig. 4 illustrates the diﬀusion of red-labelled SLNs in CF sputum.
Unlike ASM, control sputum samples revealed heterogeneity of the
sputum, where many lumps can be observed with some clear areas in
between. In general, none of the SLNs tested showed prominent colo-
calization with CF sputum, apart from scarce yellow spots in polox-
amer-stabilized SLNs, indicating non-adherence potential of the parti-
cles. C-P SLNs ﬁrst appeared in sputum half an hour following
incubation, the red ﬂuorescence gradually increases by time to be
highly signiﬁcant after 2 h, Fig. 4A. This is in line with the ﬁnding of
Yang et al. [17] that (60–80%) of poloxamer 407-coated nanoparticles
were able to penetrate physiologically thick mucus layers within 30min
regardless of the nanoparticle core composition.
Pluronic may coat hydrophobic SLNs’ surface by adsorption through
the hydrophobic polypropylene oxide segments, leaving a dense brush
of hydrophilic polyethylene oxide segments protruding from the par-
ticle surface [17]. Similar achievement was recorded for polystyrene
particles coated with polyethylene glycol with a molecular weight as
high as 3.4 kDa [16]. Noteworthy, PEG coating of molecular
weight> 5 KDa failed to penetrate due to chain entanglement with
mucus network [38].
In comparison, the diﬀusion of NR-C-Tw SLNs showed lower rate
(SLNs appeared after 1 h) and extent, Fig. 4B. C-PVA SLNs were ex-
tensively immobilized (red spots ﬁrst detected after 2 h), ﬂuorescence
remained very weak till the end of the experiment, Fig. 4C. Particle
diﬀusion ranking obtained with CF-sputum is in accordance with that in
case of ASM with certain delay presumably related to diﬀerence in
viscosity. The three types of SLNs studied were in the size range
90–260 nm. According to Suk et al. [16], the average 3D mesh spacing
of CF sputum is around 60–300 nm as determined by an obstruction
scaling model, meanwhile SEM revealed a pore size between 100 and
400 nm. An even larger pore size distribution was also described in
literature. Preclusion of SLNs’ transport cannot be exclusively explained
on size basis as a priori. Indeed, 100-nm nanospheres were more im-
mobilized in mucus compared to 200-nm ones suggesting longer
timescale interactions and functional immobilization of the smaller
beads owing to greater access to matrix sites [39].
The 3D-CLSM time laps imaging technique generally allowed the
diﬀerentiation among the three types of SLNs tested in terms of both
Table 2b
Viability of Calu-3 AIC after incubation with SLNs for 4 and 24 h.
Formula code % viability ± SDa
4 h 24 h
C-P SLNs 98.83 ± 4.48 92.59 ± 17.11
C-Tw SLNs 99.59 ± 11.26 95.24 ± 11.09
C-PVA SLNs 101.32 ± 9.92 99.75 ± 13.62
a SD denotes standard deviation (n=3).
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rate and magnitude and thus overcoming numerous drawbacks asso-
ciated to reported techniques. In an attempt to evaluate where this
technique stands relative to reported alternatives, certain points are to
be elucidated.
With regards to studying diﬀusion through a porous or foam-like
medium, which is a ﬁtting description for mucus, two types of experi-
mental setups are commonly used: (1) Diﬀusion through chamber/
reservoir, and (2) Diﬀusion within a ﬁnite gel volume [40]. Earliest
mucus penetration studies belonging to the ﬁrst category involved the
use of modiﬁed vertical diﬀusion cell containing a snapwell for holding
mucus samples [2]. Unfortunately, the prolonged incubation time, use
of a spacer as intermediate between mucus and buﬀer both might alter
the mucus/membrane conduction properties and boundary conditions
and represented an additional barrier for particles rendering the
0.5 h
1 h 2 h
4 h
6 h
24 h
2 h
3 h
24 h
Control Calu-3 cells
0.5 h
6 h
4 h
24 h
0.5 h
2 h
C-P-SLNs C-Tw-SLNs C-PVA-SLNs
Fig. 5. Z-stacks of particle diﬀusion (red) in Calu-
3 AIC (green) as a function of time: (A) C-P SLNs;
(B) C-Tw SLNs; (C) C-PVA SLNs. (For interpreta-
tion of the references to color in this ﬁgure le-
gend, the reader is referred to the web version of
this article.)
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simulation of the in vivo situation limited [9,41,42]. In addition, any
speciﬁc molecular interaction of particles with mucus could not be
determined during the experiment, since there was no direct observa-
tion of the barrier itself, together with the leakage of the mucus gel into
solution represent possible sources of errors [40].
Dünnhaupt et al. [43] introduced mucus-ﬁlled silicone tubes as
model to compare the penetration behaviour of labelled unmodiﬁed as
well as thiolated anionic and cationic polymeric nanoparticles. Despite
the feasibility and cost-eﬀectiveness of this method, accurate ﬁlling of
the silicone tubes with mucus without the incorporation of air bubbles
into the mucus layer is challenging. Furthermore, possible changes in
the mucus structure caused by the rotating movement must be taken
into account.
3.7. Penetration of SLNs on mucus-secreting cell lines
Calu-3 cells represent a human bronchial cell model with the ability
to produce mucus when grown at AIC. This mucus layer represents a
good platform for particle penetration studies. The technique was ﬁrst
introduced by Mura et al. [32] to study the eﬀect of surface properties
of PLGA nanoparticles on their interaction with bronchial mucus bar-
rier.
3.7.1. Colloidal stability during nebulization and cell viability
Prior to particle penetration studies on Calu-3 AIC, colloidal stabi-
lity of SLNs during nebulization with Aeroneb® Lab micropump nebu-
lizer was veriﬁed. Size measurement revealed considerable increase in
particle diameter and polydispersity in case of NR-C-P SLNs, while NR-
C-Tw and NR-C-PVA SLNs remained relatively colloidally stable,
Table 2a.
Another essential factor was to check that the nebulized SLNs as
well as the nebulization process did not negatively aﬀect the viability of
Calu-3 AIC. Table 2b depicted percentage viability> 92.5% after in-
cubation of the cells with diﬀerent SLNs for 4 and 24 h. Any harmful
eﬀect of SLNs or nebulization process on Calu-3 AIC was hence ex-
cluded.
A
B
C
Green channel Red channel Overlap
Fig. 6. Confocal images showing particle (red) interaction with mucus (green) in Calu-3 AIC: (A) C-P SLNs; (B) C-Tw SLNs; (C) C-PVA SLNs. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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3.7.2. Particle penetration
Fig. 5 illustrates the green-labelled mucus layer on the top of control
cells in the form of dense areas of ﬁbrous network with loose regions
presumably containing interstitial ﬂuid as reported [30]. Half an hour
after incubation, the red-labelled C-P SLNs could be clearly detected.
Such an observation required 2 h in case of NR-C-Tw and NR-C-PVA
SLNs. The time necessary for the particles to cross the whole mucus
layer to the cells underneath was 2 h for NR-C-P SLNs and 4 h for both
NR-C-Tw and NR-C-PVA SLNs, Fig. 5. Following longer incubation
periods (6–24 h), the upper mucus layer appeared devoid of nano-
particles, whilst the membrane of the Transwell underneath showed
intense red ﬂuorescence indicating that most of the SLNs potentially
reached the bottom of the setup.
Fig. 6 represents particle localization in one of the stacks. Closer
insights on the particle pathway within the mucus layer revealed the
mucus-escaping ability of NR-C-P SLNs, where SLNs can be detected
primarly in the vicinity of the mucus network showing signiﬁcant level
of mobility, Fig. 6A. This is in line with their diﬀusion behaviour in CF
sputum. Poloxamer obviously promoted SLN penetration in the loose
interstitial ﬂuid.
Interestingly, Tween-coated SLNs could not only eﬃciently cross the
mucus network but were also taken up by the cell monolayer under-
neath, Fig. 6B. Although neither the cell membrane nor the nuclei were
stained, SLNs appear as red spots predominantly into the cytoplasm,
Fig. 6B. Mucus interaction of Tween-coated nanoparticles was seldom
addressed so far in literature.
C-PVA SLNs underwent certain partitioning between the holes in the
mucus layer and the mucus network itself, which might be the reason
behind the aforementioned motion obstruction and the retarded diﬀu-
sion detected by all previous techniques, Fig. 6C. Keeping into con-
sideration the relatively larger particle size of C-PVA SLNs, the viscosity
imparting properties and reported mucoadhesive characters of PVA,
limited diﬀusion was well predicted [32,44].
Such observation would drive the conclusion that for the treatment
of cystic ﬁbrosis, C-P SLNs represent the fastest formulation crossing
mucus. C-Tw SLNs would be the most suitable choice when intracellular
targeting and gene repair are in question, while C-PVA SLNs ensure
longer residence in the mucus layer and would be hence better suiting
infected mucosal layer.
Interestingly, Calu-3 AIC allowed longer study periods up to 24 h
unlike ASM & CF-sputum (2–3 h). Accordingly, Calu-3 cells enabled
investigation of not only particle diﬀusion in mucus but also particle
uptake by the cells. After 24 h, the red-labelled SLNs could be clearly
detected below the stained mucus layer, Fig. 5. Previous studies carried
out using mucus producing cell models e.g. HT29-MTX goblet cell line
were also reported successful particle permeation followed by cellular
uptake [39]. Following incubation with ﬂuospheres (200 nm), uptake
was determined by ﬂow cytometry [39]. Data obtained were in good
complement with the ﬂuorescence recovery after photobleaching
(FRAP) experiment used to study particle diﬀusion in native gastric pig
mucus. However, it is to be noted that mucins produced by cancer cell
lines such as the aforementioned colorectal cancer cells have shorter
carbohydrate chains, which could alter the gel structure [45].
Additional consideration of using Calu-3 AIC for studying particle-
mucus interaction is that the mucus layer produced on cell surface – as
expected from living organisms – was of variable thickness and het-
erogeneous network density, which might ultimately lead to dis-
crepancies in particle diﬀusion rate. Variable thickness might not only
be observed among variable samples but also with cells grown for
longer periods incubated with the same sample. Longer incubation is
most likely accompanied by thicker mucus layer and thereby longer
diﬀusion pathway.
3.7.3. ASM versus CF sputum versus Calu-3 cells (image analysis)
Concerns with the native mucus gel have led to the exploration of
other media as models for mucus diﬀusion. Puriﬁed mucus, commer-
cially synthesized mucin, porous membranes and non-crosslinking
polymer gels have been employed as alternatives to native mucus. In
addition, research into cell lines secreting mucus, and recent eﬀort to
produce an ex vivo epithelium mucus model help to open new possi-
bilities for transmucosal delivery models as reviewed by Cu and
Saltzman [40].
To enable quantitative comparison between the rate and extent of
particle penetration in diﬀerent mucus samples (ASM, CF sputum and
Calu-3 cells), the total ﬂuorescence signal of combined 3D laps for each
particle sample at diﬀerent time points was analysed using image
analysis software. When ASM was used, ﬂuorescence signal of C-P SLNs
after 30min was 6 and 75 times higher than C-Tw and C-PVA SLNs,
respectively, Fig. 7A. Viscous mucus samples like CF sputum restricted
SLN penetration during the ﬁrst hour regardless of the type of hydro-
philic coating used. Later on, Tween appeared relatively more eﬃcient
than poloxamer in managing particle diﬀusion in CF sputum as revealed
from the total ﬂuorescence signal illustrated in Fig. 7B, except for the
180min time point. Diﬀusion of PVA-coated SLNs remained limited
along the study period (3h).
However, mucus penetration on Calu-3 cells showed diﬀerent
Fig. 7. Total ﬂuorescence signal of SLNs in: (A) ASM; (B) CF sputum; (C) Calu-3 AIC
determined by image analysis software.
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behaviour, where Tween showed excellent mucus-escaping ability
starting from the ﬁrst half an hour, Fig. 7C. Fluorescence gradually
increased by time up to 6 h for both C-Tw and C-P SLNs, where again C-
Tw predominantly showed superior ﬂuorescence meanwhile, that of C-
PVA SLNs remained insigniﬁcant. After 24 h incubation, weak ﬂuores-
cence signal was recorded for all samples in the mucus layer denoting
complete migration of SLNs to the underlying cell monolayer.
Despite the signiﬁcant in vivomimicking potential of Calu-3 AIC, the
lack of reproducibility holds certain caution towards their application
in mucus penetration studies. The nanoscale structural, viscoelastic and
barrier properties of mucus on Calu-3 cells relative to CF sputum merit
further investigations. Besides, the aforementioned techniques do not
keep the factor of mucin turnover into consideration; in case of CF
patients where mucociliary clearance is prohibited this won’t be an
issue. However, similar studies related to other transmucosal delivery
routes, where mucin turnover is predominant, would worth certain
modiﬁcations to accomplish this factor.
4. Conclusions
The work provides insights into studying the ability of nanoparticles
- namely SLNs of diﬀerent surface properties – to cross pulmonary
mucus barrier. Poloxamer-coated SLNs showed faster diﬀusion rate in
mucus followed by Tween-coated SLNs, whereas PVA coating ensured
very weak mucus penetration. To our knowledge, this is the ﬁrst study
addressing SLNs and deeply investigating mucus-particle interaction
using micro- and macro-displacement analyses. Results emphasised
perfect correlation between both techniques.
In addition, the inﬂuence of mucus nature (ASM, native CF sputum
and mucus on the top of cell lines) on particle penetration ability is well
highlighted. While ASM seems more appealing, practical and adequate
to investigate particle interaction with mucus components, its low
viscosity and poor rheological behaviour might lead to false inter-
pretations. Remarkably, substituting ASM with CF sputum only slowed
down the diﬀusion of SLNs presumably owing to alteration in the type
of diﬀusion; the ranking albeit remained unaltered. However, dis-
crepancies among sputum samples and heterogeneous intra-sample
structure make reproducibility rather challenging. Mucus-secreting
cells allowed longer study periods (24 h), hence, enabling investigation
of mucus diﬀusion as well as cellular uptake. However, varying struc-
tural, viscoelastic and barrier properties of mucus on cancer cell lines
relative to CF sputum are to be pointed out.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.ejpb.2017.12.017.
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